http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 10 Mar 2026 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Alnylam+to+Webcast+TTR+Investor+Webinar/26135566.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alnylam.com%2F&amp;esheet=54442893&amp;newsitemid=20260310495157&amp;lan=en-US&amp;anchor=Alnylam+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=624cc8dda767551fb206426ac15fd6c2" shape="rect">Alnylam Pharmaceuticals, Inc.</a> (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the Investors section of the Company’s website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alnylam.com&amp;esheet=54442893&amp;newsitemid=20260310495157&amp;lan=en-US&amp;anchor=www.alnylam.com&amp;index=2&amp;md5=d72623a77fb0236c996f6642b77a092b" shape="rect">www.alnylam.com</a>, on Tuesday, March 24, 2026 at 9:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event. </p><p> The TTR Investor Webinar, marking one year since U.S. FDA approval of AMVUTTRA® in ATTR-CM, will highlight Alnylam’s progress in delivering for patients with ATTR-CM, as well as the long-term growth and durability http://www.streetinsider.com/Press+Releases/Alnylam+to+Webcast+TTR+Investor+Webinar/26135566.html Tue, 10 Mar 2026 08:00:00 -0400 ALNY O.00980119 http://www.streetinsider.com/Press+Releases/Alnylam+to+Webcast+TTR+Investor+Webinar/26135566.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alnylam.com%2F&amp;esheet=54442893&amp;newsitemid=20260310495157&amp;lan=en-US&amp;anchor=Alnylam+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=624cc8dda767551fb206426ac15fd6c2" shape="rect">Alnylam Pharmaceuticals, Inc.</a> (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the Investors section of the Company’s website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alnylam.com&amp;esheet=54442893&amp;newsitemid=20260310495157&amp;lan=en-US&amp;anchor=www.alnylam.com&amp;index=2&amp;md5=d72623a77fb0236c996f6642b77a092b" shape="rect">www.alnylam.com</a>, on Tuesday, March 24, 2026 at 9:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event. </p><p> The TTR Investor Webinar, marking one year since U.S. FDA approval of AMVUTTRA® in ATTR-CM, will highlight Alnylam’s progress in delivering for patients with ATTR-CM, as well as the long-term growth and durability http://www.streetinsider.com/Press+Releases/Alnylam+to+Webcast+TTR+Investor+Webinar/26135566.html Tue, 10 Mar 2026 08:00:00 -0400 ALNY O.00980119 http://www.streetinsider.com/Business+Wire/Alnylam+to+Webcast+TTR+Investor+Webinar/26135566.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alnylam.com%2F&amp;esheet=54442893&amp;newsitemid=20260310495157&amp;lan=en-US&amp;anchor=Alnylam+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=624cc8dda767551fb206426ac15fd6c2" shape="rect">Alnylam Pharmaceuticals, Inc.</a> (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the Investors section of the Company’s website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alnylam.com&amp;esheet=54442893&amp;newsitemid=20260310495157&amp;lan=en-US&amp;anchor=www.alnylam.com&amp;index=2&amp;md5=d72623a77fb0236c996f6642b77a092b" shape="rect">www.alnylam.com</a>, on Tuesday, March 24, 2026 at 9:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event. </p><p> The TTR Investor Webinar, marking one year since U.S. FDA approval of AMVUTTRA® in ATTR-CM, will highlight Alnylam’s progress in delivering for patients with ATTR-CM, as well as the long-term growth and durability http://www.streetinsider.com/Business+Wire/Alnylam+to+Webcast+TTR+Investor+Webinar/26135566.html Tue, 10 Mar 2026 08:00:00 -0400 ALNY O.00980119 http://www.streetinsider.com/Business+Wire/Alnylam+to+Webcast+TTR+Investor+Webinar/26135566.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alnylam.com%2F&amp;esheet=54442893&amp;newsitemid=20260310495157&amp;lan=en-US&amp;anchor=Alnylam+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=624cc8dda767551fb206426ac15fd6c2" shape="rect">Alnylam Pharmaceuticals, Inc.</a> (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the Investors section of the Company’s website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alnylam.com&amp;esheet=54442893&amp;newsitemid=20260310495157&amp;lan=en-US&amp;anchor=www.alnylam.com&amp;index=2&amp;md5=d72623a77fb0236c996f6642b77a092b" shape="rect">www.alnylam.com</a>, on Tuesday, March 24, 2026 at 9:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event. </p><p> The TTR Investor Webinar, marking one year since U.S. FDA approval of AMVUTTRA® in ATTR-CM, will highlight Alnylam’s progress in delivering for patients with ATTR-CM, as well as the long-term growth and durability http://www.streetinsider.com/Business+Wire/Alnylam+to+Webcast+TTR+Investor+Webinar/26135566.html Tue, 10 Mar 2026 08:00:00 -0400 ALNY O.00980119 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALNYLAM+PHARMACEUTICALS%2C++For%3A+Mar+04++Filed+by%3A+Garg+Pushkal/26125594.html si-local-file:///var/storage/secattach/20260306/26125594.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALNYLAM+PHARMACEUTICALS%2C++For%3A+Mar+04++Filed+by%3A+Garg+Pushkal/26125594.html Fri, 06 Mar 2026 16:14:00 -0400 ALNY O.00980119 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALNYLAM+PHARMACEUTICALS%2C++For%3A+Mar+04++Filed+by%3A+Garg+Pushkal/26125594.html si-local-file:///var/storage/secattach/20260306/26125594.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALNYLAM+PHARMACEUTICALS%2C++For%3A+Mar+04++Filed+by%3A+Garg+Pushkal/26125594.html Fri, 06 Mar 2026 16:14:00 -0400 ALNY O.00980119 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALNYLAM+PHARMACEUTICALS%2C++For%3A+Mar+04++Filed+by%3A+Greenstreet+Yvonne/26125587.html si-local-file:///var/storage/secattach/20260306/26125587.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALNYLAM+PHARMACEUTICALS%2C++For%3A+Mar+04++Filed+by%3A+Greenstreet+Yvonne/26125587.html Fri, 06 Mar 2026 16:13:00 -0400 ALNY O.00980119 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALNYLAM+PHARMACEUTICALS%2C++For%3A+Mar+04++Filed+by%3A+Greenstreet+Yvonne/26125587.html si-local-file:///var/storage/secattach/20260306/26125587.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALNYLAM+PHARMACEUTICALS%2C++For%3A+Mar+04++Filed+by%3A+Greenstreet+Yvonne/26125587.html Fri, 06 Mar 2026 16:13:00 -0400 ALNY O.00980119 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALNYLAM+PHARMACEUTICALS%2C++For%3A+Mar+04++Filed+by%3A+Fitzgerald+Kevin+Joseph/26125553.html si-local-file:///var/storage/secattach/20260306/26125553.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALNYLAM+PHARMACEUTICALS%2C++For%3A+Mar+04++Filed+by%3A+Fitzgerald+Kevin+Joseph/26125553.html Fri, 06 Mar 2026 16:12:00 -0400 ALNY O.00980119 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALNYLAM+PHARMACEUTICALS%2C++For%3A+Mar+04++Filed+by%3A+Fitzgerald+Kevin+Joseph/26125553.html si-local-file:///var/storage/secattach/20260306/26125553.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALNYLAM+PHARMACEUTICALS%2C++For%3A+Mar+04++Filed+by%3A+Fitzgerald+Kevin+Joseph/26125553.html Fri, 06 Mar 2026 16:12:00 -0400 ALNY O.00980119 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALNYLAM+PHARMACEUTICALS%2C++For%3A+Mar+04++Filed+by%3A+Tanguler+Tolga/26125569.html si-local-file:///var/storage/secattach/20260306/26125569.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALNYLAM+PHARMACEUTICALS%2C++For%3A+Mar+04++Filed+by%3A+Tanguler+Tolga/26125569.html Fri, 06 Mar 2026 16:12:00 -0400 ALNY O.00980119 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALNYLAM+PHARMACEUTICALS%2C++For%3A+Mar+04++Filed+by%3A+Tanguler+Tolga/26125569.html si-local-file:///var/storage/secattach/20260306/26125569.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALNYLAM+PHARMACEUTICALS%2C++For%3A+Mar+04++Filed+by%3A+Tanguler+Tolga/26125569.html Fri, 06 Mar 2026 16:12:00 -0400 ALNY O.00980119 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALNYLAM+PHARMACEUTICALS%2C++For%3A+Mar+04++Filed+by%3A+Poulton+Jeffrey+V./26125576.html si-local-file:///var/storage/secattach/20260306/26125576.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALNYLAM+PHARMACEUTICALS%2C++For%3A+Mar+04++Filed+by%3A+Poulton+Jeffrey+V./26125576.html Fri, 06 Mar 2026 16:12:00 -0400 ALNY O.00980119 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALNYLAM+PHARMACEUTICALS%2C++For%3A+Mar+04++Filed+by%3A+Poulton+Jeffrey+V./26125576.html si-local-file:///var/storage/secattach/20260306/26125576.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ALNYLAM+PHARMACEUTICALS%2C++For%3A+Mar+04++Filed+by%3A+Poulton+Jeffrey+V./26125576.html Fri, 06 Mar 2026 16:12:00 -0400 ALNY O.00980119 http://www.streetinsider.com/SEC+Filings/Form++144++++++++ALNYLAM+PHARMACEUTICALS%2C+++++++++++++++Filed+by%3A+Fitzgerald+Kevin+Joseph/26118731.html si-local-file:///var/storage/secattach/20260305/26118731.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++ALNYLAM+PHARMACEUTICALS%2C+++++++++++++++Filed+by%3A+Fitzgerald+Kevin+Joseph/26118731.html Thu, 05 Mar 2026 16:04:00 -0400 ALNY O.00980119 http://www.streetinsider.com/SEC+Filings/Form++144++++++++ALNYLAM+PHARMACEUTICALS%2C+++++++++++++++Filed+by%3A+Fitzgerald+Kevin+Joseph/26118731.html si-local-file:///var/storage/secattach/20260305/26118731.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++ALNYLAM+PHARMACEUTICALS%2C+++++++++++++++Filed+by%3A+Fitzgerald+Kevin+Joseph/26118731.html Thu, 05 Mar 2026 16:04:00 -0400 ALNY O.00980119 http://www.streetinsider.com/SEC+Filings/Form++144++++++++ALNYLAM+PHARMACEUTICALS%2C+++++++++++++++Filed+by%3A+Garg+Pushkal/26118708.html si-local-file:///var/storage/secattach/20260305/26118708.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++ALNYLAM+PHARMACEUTICALS%2C+++++++++++++++Filed+by%3A+Garg+Pushkal/26118708.html Thu, 05 Mar 2026 16:03:00 -0400 ALNY O.00980119 http://www.streetinsider.com/SEC+Filings/Form++144++++++++ALNYLAM+PHARMACEUTICALS%2C+++++++++++++++Filed+by%3A+Garg+Pushkal/26118708.html si-local-file:///var/storage/secattach/20260305/26118708.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++ALNYLAM+PHARMACEUTICALS%2C+++++++++++++++Filed+by%3A+Garg+Pushkal/26118708.html Thu, 05 Mar 2026 16:03:00 -0400 ALNY O.00980119 http://www.streetinsider.com/Corporate+News/Tenaya+Therapeutics+partners+with+Alnylam+for+heart+disease+targets/26115743.html <p>Tenaya Therapeutics Inc. (NASDAQ: TNYA) announced a research collaboration agreement with Alnylam Pharmaceuticals (NASDAQ: ALNY) to discover genetic targets for cardiovascular disease treatments.</p><p>Under the agreement, Tenaya will validate up to 15 gene targets over a two-year period. The company will receive up to $10 million in upfront payments plus reimbursement for related costs. Alnylam will handle all development and commercialization activities for therapeutics associated with the identified targets.</p><p>Tenaya may receive up to $1.13 billion in development and commercial milestone payments if all genetic targets lead to approved cardiovascular disease therapeutics, according to the press release.</p><p>"By combining our modality agnostic target http://www.streetinsider.com/Corporate+News/Tenaya+Therapeutics+partners+with+Alnylam+for+heart+disease+targets/26115743.html Thu, 05 Mar 2026 08:31:42 -0400 ALNY TNYA http://www.streetinsider.com/Corporate+News/Tenaya+Therapeutics+partners+with+Alnylam+for+heart+disease+targets/26115743.html <p>Tenaya Therapeutics Inc. (NASDAQ: TNYA) announced a research collaboration agreement with Alnylam Pharmaceuticals (NASDAQ: ALNY) to discover genetic targets for cardiovascular disease treatments.</p><p>Under the agreement, Tenaya will validate up to 15 gene targets over a two-year period. The company will receive up to $10 million in upfront payments plus reimbursement for related costs. Alnylam will handle all development and commercialization activities for therapeutics associated with the identified targets.</p><p>Tenaya may receive up to $1.13 billion in development and commercial milestone payments if all genetic targets lead to approved cardiovascular disease therapeutics, according to the press release.</p><p>"By combining our modality agnostic target http://www.streetinsider.com/Corporate+News/Tenaya+Therapeutics+partners+with+Alnylam+for+heart+disease+targets/26115743.html Thu, 05 Mar 2026 08:31:42 -0400 ALNY TNYA http://www.streetinsider.com/Press+Releases/Tenaya+Therapeutics+Enters+into+Research+Collaboration+with+Alnylam+Pharmaceuticals+to+Identify+and+Validate+Novel+Genetic+Targets+for+Cardiovascular+Disease+Therapeutics/26115714.html <p align="center"><em>Agreement Combines Tenaya’s Expertise in Identification and Validation of<br/></em><em>Genetic Heart Disease Targets with Alnylam’s Ability to Deliver Transformational Therapeutics</em></p> <p align="center"><em>Tenaya to Receive Up to $10 Million in Upfront Payments in Addition to Research Funding and Milestone Payments of Up to $1.13 Billion</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced a research collaboration agreement with Alnylam Pharmaceuticals (Nasdaq: ALNY), the leading RNAi http://www.streetinsider.com/Press+Releases/Tenaya+Therapeutics+Enters+into+Research+Collaboration+with+Alnylam+Pharmaceuticals+to+Identify+and+Validate+Novel+Genetic+Targets+for+Cardiovascular+Disease+Therapeutics/26115714.html Thu, 05 Mar 2026 08:30:00 -0400 ALNY O.00980119 O.34342580 TNYA http://www.streetinsider.com/Press+Releases/Tenaya+Therapeutics+Enters+into+Research+Collaboration+with+Alnylam+Pharmaceuticals+to+Identify+and+Validate+Novel+Genetic+Targets+for+Cardiovascular+Disease+Therapeutics/26115714.html <p align="center"><em>Agreement Combines Tenaya’s Expertise in Identification and Validation of<br/></em><em>Genetic Heart Disease Targets with Alnylam’s Ability to Deliver Transformational Therapeutics</em></p> <p align="center"><em>Tenaya to Receive Up to $10 Million in Upfront Payments in Addition to Research Funding and Milestone Payments of Up to $1.13 Billion</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced a research collaboration agreement with Alnylam Pharmaceuticals (Nasdaq: ALNY), the leading RNAi http://www.streetinsider.com/Press+Releases/Tenaya+Therapeutics+Enters+into+Research+Collaboration+with+Alnylam+Pharmaceuticals+to+Identify+and+Validate+Novel+Genetic+Targets+for+Cardiovascular+Disease+Therapeutics/26115714.html Thu, 05 Mar 2026 08:30:00 -0400 ALNY O.00980119 O.34342580 TNYA http://www.streetinsider.com/Press+Releases/Tenaya+Therapeutics+Enters+into+Research+Collaboration+with+Alnylam+Pharmaceuticals+to+Identify+and+Validate+Novel+Genetic+Targets+for+Cardiovascular+Disease+Therapeutics/26115714.html <p align="center"><em>Agreement Combines Tenaya’s Expertise in Identification and Validation of<br/></em><em>Genetic Heart Disease Targets with Alnylam’s Ability to Deliver Transformational Therapeutics</em></p> <p align="center"><em>Tenaya to Receive Up to $10 Million in Upfront Payments in Addition to Research Funding and Milestone Payments of Up to $1.13 Billion</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced a research collaboration agreement with Alnylam Pharmaceuticals (Nasdaq: ALNY), the leading RNAi http://www.streetinsider.com/Press+Releases/Tenaya+Therapeutics+Enters+into+Research+Collaboration+with+Alnylam+Pharmaceuticals+to+Identify+and+Validate+Novel+Genetic+Targets+for+Cardiovascular+Disease+Therapeutics/26115714.html Thu, 05 Mar 2026 08:30:00 -0400 ALNY O.00980119 O.34342580 TNYA http://www.streetinsider.com/Press+Releases/Tenaya+Therapeutics+Enters+into+Research+Collaboration+with+Alnylam+Pharmaceuticals+to+Identify+and+Validate+Novel+Genetic+Targets+for+Cardiovascular+Disease+Therapeutics/26115714.html <p align="center"><em>Agreement Combines Tenaya’s Expertise in Identification and Validation of<br/></em><em>Genetic Heart Disease Targets with Alnylam’s Ability to Deliver Transformational Therapeutics</em></p> <p align="center"><em>Tenaya to Receive Up to $10 Million in Upfront Payments in Addition to Research Funding and Milestone Payments of Up to $1.13 Billion</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced a research collaboration agreement with Alnylam Pharmaceuticals (Nasdaq: ALNY), the leading RNAi http://www.streetinsider.com/Press+Releases/Tenaya+Therapeutics+Enters+into+Research+Collaboration+with+Alnylam+Pharmaceuticals+to+Identify+and+Validate+Novel+Genetic+Targets+for+Cardiovascular+Disease+Therapeutics/26115714.html Thu, 05 Mar 2026 08:30:00 -0400 ALNY O.00980119 O.34342580 TNYA http://www.streetinsider.com/Globe+Newswire/Tenaya+Therapeutics+Enters+into+Research+Collaboration+with+Alnylam+Pharmaceuticals+to+Identify+and+Validate+Novel+Genetic+Targets+for+Cardiovascular+Disease+Therapeutics/26115714.html <p align="center"><em>Agreement Combines Tenaya’s Expertise in Identification and Validation of<br/></em><em>Genetic Heart Disease Targets with Alnylam’s Ability to Deliver Transformational Therapeutics</em></p> <p align="center"><em>Tenaya to Receive Up to $10 Million in Upfront Payments in Addition to Research Funding and Milestone Payments of Up to $1.13 Billion</em></p> <p align="justify">SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced a research collaboration agreement with Alnylam Pharmaceuticals (Nasdaq: ALNY), the leading RNAi http://www.streetinsider.com/Globe+Newswire/Tenaya+Therapeutics+Enters+into+Research+Collaboration+with+Alnylam+Pharmaceuticals+to+Identify+and+Validate+Novel+Genetic+Targets+for+Cardiovascular+Disease+Therapeutics/26115714.html Thu, 05 Mar 2026 08:30:00 -0400 ALNY O.00980119 O.34342580 TNYA